HomeCompareNHMAF vs ABBV

NHMAF vs ABBV: Dividend Comparison 2026

NHMAF yields 4.22% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NHMAF wins by $2413.90M in total portfolio value· pulled ahead in Year 2
10 years
NHMAF
NHMAF
● Live price
4.22%
Share price
$3.79
Annual div
$0.16
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2414.00M
Annual income
$2,308,935,124.83
Full NHMAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NHMAF vs ABBV

📍 NHMAF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNHMAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NHMAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NHMAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NHMAF
Annual income on $10K today (after 15% tax)
$358.84/yr
After 10yr DRIP, annual income (after tax)
$1,962,594,856.11/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NHMAF beats the other by $1,962,573,800.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NHMAF + ABBV for your $10,000?

NHMAF: 50%ABBV: 50%
100% ABBV50/50100% NHMAF
Portfolio after 10yr
$1207.05M
Annual income
$1,154,479,948.30/yr
Blended yield
95.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NHMAF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NHMAF buys
0
ABBV buys
0
No recent congressional trades found for NHMAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNHMAFABBV
Forward yield4.22%3.06%
Annual dividend / share$0.16$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$2414.00M$102.3K
Annual income after 10y$2,308,935,124.83$24,771.77
Total dividends collected$2406.53M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NHMAF vs ABBV ($10,000, DRIP)

YearNHMAF PortfolioNHMAF Income/yrABBV PortfolioABBV Income/yrGap
1$11,544$844.33$11,550$430.00$6.00ABBV
2← crossover$14,174$1,821.90$13,472$627.96+$702.00NHMAF
3$19,348$4,181.25$15,906$926.08+$3.4KNHMAF
4$31,370$10,667.94$19,071$1,382.55+$12.3KNHMAF
5$65,896$32,330.41$23,302$2,095.81+$42.6KNHMAF
6$197,451$126,941.45$29,150$3,237.93+$168.3KNHMAF
7$922,234$710,962.18$37,536$5,121.41+$884.7KNHMAF
8$7,193,702$6,206,911.70$50,079$8,338.38+$7.14MNHMAF
9$98,194,011$90,496,749.43$69,753$14,065.80+$98.12MNHMAF
10$2,414,002,717$2,308,935,124.83$102,337$24,771.77+$2413.90MNHMAF

NHMAF vs ABBV: Complete Analysis 2026

NHMAFStock

Nihon M&A Center Holdings Inc. provides mergers and acquisition (M&A) related services in Japan and internationally. The company offers M&A support services, such as reorganization, capital policies, and MBO for small and medium-sized enterprises. It is also involved in marketing research and consulting activities. Nihon M&A Center Holdings Inc. was incorporated in 1991 and is headquartered in Tokyo, Japan.

Full NHMAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NHMAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NHMAF vs SCHDNHMAF vs JEPINHMAF vs ONHMAF vs KONHMAF vs MAINNHMAF vs JNJNHMAF vs MRKNHMAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.